-+ 0.00%
-+ 0.00%
-+ 0.00%

Kodiak Sciences to present Phase 3 DAYBREAK wet AMD data for Zenkuda at AAO 2026

PUBT·10/07/2026 11:01:51
Listen to the news
Kodiak Sciences to present Phase 3 DAYBREAK wet AMD data for Zenkuda at AAO 2026
  • Kodiak Sciences flagged upcoming AAO 2026 presentations covering three late-stage retina programs, led by first scientific disclosure of Phase 3 DAYBREAK.
  • DAYBREAK topline results were released Sept. 28, 2026; detailed one-year efficacy and safety data will be presented Oct. 9, 2026.
  • Both Zenkuda and tabirafusp-ted achieved vision outcomes comparable to aflibercept at year one, supporting competitive positioning in wet AMD.
  • AAO 2026 will also feature Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, extending its late-stage readout set.
  • Phase 1b APEX data for KSI-101 in inflammation-related macular edema will be presented, adding early clinical support for a separate program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070700PR_NEWS_USPR_____SF65648) on October 07, 2026, and is solely responsible for the information contained therein.